Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound preparation containing benidipine hydrochloride and benazepril hydrochloride, as well as application thereof

A technology of benazepril hydrochloride and benidipine hydrochloride, which is applied in the field of biomedicine, can solve the problems of inaccurate dosage, influence of drug efficacy, and increase of drug side effects, so as to improve antihypertensive efficacy, enhance therapeutic effect, and improve drug use. Dose Reduction Effects

Inactive Publication Date: 2012-03-28
济南龙华医药技术有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] When using benidipine hydrochloride or benazepril hydrochloride clinically now, there are often the following problems: 1. When using a single drug, the dosage of the drug must be increased to ensure the curative effect, which will inevitably lead to a significant increase in side effects of the drug; 2. When taking medication, because there is no pharmaceutical preparation that meets the dosage of the combined medication, the dosage used for clinical use is inaccurate, which affects the efficacy of the medication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation containing benidipine hydrochloride and benazepril hydrochloride, as well as application thereof
  • Compound preparation containing benidipine hydrochloride and benazepril hydrochloride, as well as application thereof
  • Compound preparation containing benidipine hydrochloride and benazepril hydrochloride, as well as application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] 1 part by weight of benidipine hydrochloride, 5 parts by weight of benazepril hydrochloride, 40.25 parts by weight of lactose, 20 parts by weight of microcrystalline cellulose, 40 parts by weight of pregelatinized starch, 15 parts by weight of sodium carboxymethyl starch, hypromellose 2.5 parts by weight of magnesium stearate and 1.25 parts by weight of magnesium stearate.

[0022] The raw materials and auxiliary materials are respectively pulverized through 80-mesh sieves, and the hypromellose is prepared with purified water to a suitable concentration as a binder for later use. Except for magnesium stearate, mix other raw and auxiliary materials uniformly by the method of equal incremental dilution, use the prepared adhesive to make a soft material, pass through a 18-mesh sieve for granulation, fully dry at 60°C, and granulate with an 18-mesh sieve. Add the prescribed amount of magnesium stearate, mix evenly, compress into tablets, and coat. Each tablet contains 1 mg...

Embodiment 2

[0024] 2 parts by weight of benidipine hydrochloride, 10 parts by weight of benazepril hydrochloride, 30 parts by weight of microcrystalline cellulose, 58 parts by weight of pregelatinized starch, 20 parts by weight of sodium carboxymethyl starch, 3 parts by weight of povidone K30, hard 2.5 parts by weight of magnesium fatty acid.

[0025] The raw materials and auxiliary materials were crushed through an 80-mesh sieve, and the povidone K30 was prepared with purified water to a suitable concentration as a binder for later use. Except for magnesium stearate, other raw and auxiliary materials are mixed uniformly by the method of equal incremental dilution, and the soft material is made of the prepared adhesive, granulated through a 20-mesh sieve, fully dried at 65°C, and granulated with a 20-mesh sieve. Add the prescribed amount of magnesium stearate, mix evenly, compress into tablets, and coat. Each tablet contains benidipine hydrochloride 2 mg and benazepril hydrochloride 10 m...

Embodiment 3

[0027] 1 part by weight of benidipine hydrochloride, 5 parts by weight of benazepril hydrochloride, 30 parts by weight of lactose, 37 parts by weight of microcrystalline cellulose, 29.5 parts by weight of pregelatinized starch, 18 parts by weight of croscarmellose sodium, Promellose 3 parts by weight, magnesium stearate 1.5 parts by weight.

[0028] The raw materials and auxiliary materials are respectively crushed through an 80-mesh sieve, and the hypromellose is prepared with purified water to a suitable concentration as a binder for later use. Except for magnesium stearate, other raw and auxiliary materials are mixed evenly by the method of equal incremental dilution, and the soft material is made of the prepared adhesive, granulated through a 18-mesh sieve, fully dried at 70°C, and granulated with an 18-mesh sieve. Add the prescribed amount of magnesium stearate, mix evenly, compress into tablets, and coat. Each tablet contains 1 mg of benidipine hydrochloride and 5 mg of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound preparation containing benidipine hydrochloride and benazepril hydrochloride, as well as application thereof, wherein preparation containing benidipine hydrochloride and benazepril hydrochloride serve as effective components of the medicament. According to the compound preparation, the defects of large dose and high side effect of single drug are overcome, and the compound preparation disclosed by the invention is obtained by compounding the benidipine hydrochloride and benazepril hydrochloride. Oral preparations with different forms can be prepared by the preparation, due to synergic and complementary effects of medicaments, the compound preparation has reinforced treatment effect, the medicament dose is reduced in clinical application, adverse reaction of a patient is lightened, and the compound preparation can be accepted easily. The compound preparation has remarkable treatment effect in mild and severe hypertension, and is suitable for hypertension patient with cardiovascular remodeling, and patients with renal hypertension, hypertension with renal damage or with diabetic renal damage. Furthermore, the compound preparation has low price, simple preparation and easy popularization and application.

Description

technical field [0001] The invention relates to a compound preparation and an application thereof, in particular to a compound preparation containing benidipine hydrochloride and benazepril hydrochloride and an application thereof, belonging to the technical field of biomedicine. Background technique [0002] Hypertension is the most prevalent disease in the world today, known as the "silent killer". According to the global burden of disease survey in 2000, 50% of cardiovascular diseases are caused by high blood pressure, which accounts for 4.5% of the current global disease burden. High blood pressure is common in both developed and developing countries. At present, about 25% to 35% of adults in the world are hypertensive patients, and the total number of hypertensive patients reaches 972 million; while the number of people over 70 years old rises to 60% to 70%. Among the causes of death of people over 40 years old in my country, heart disease and cerebrovascular disease r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/55A61K31/4545A61P9/12
Inventor 马全龙初茂忠王淑云王浩骅梁海勇孙山
Owner 济南龙华医药技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com